βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure

被引:47
作者
Batista Ferreira, Julio Cesar [1 ,2 ]
Brum, Patricia Chakur [2 ]
Mochly-Rosen, Daria [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Chem & Syst Biol, CCSR, Stanford, CA 94305 USA
[2] Univ Sao Paulo, Sch Phys Educ & Sport, BR-05508900 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
PKC signaling pathways; Cardiac remodeling; Heart failure; PROTEIN-KINASE-C; ISOFORM EXPRESSION; DELTA-PKC; DIFFERENTIAL ACTIVATION; VENTRICULAR HYPERTROPHY; SUDDEN-DEATH; RAT; INHIBITION; ALPHA; HYPERTENSION;
D O I
10.1016/j.yjmcc.2010.10.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac hypertrophy is a complex adaptive response to mechanical and neurohumoral stimuli and under continual stressor, it contributes to maladaptive responses, heart failure and death. Protein kinase C (PKC) and several other kinases play a role in the maladaptative cardiac responses, including cardiomyocyte hypertrophy, myocardial fibrosis and inflammation. Identifying specific therapies that regulate these kinases is a major focus of current research. PKC, a family of serine/threonine kinases, has emerged as potential mediators of hypertrophic stimuli associated with neurohumoral hyperactivity in heart failure. In this review, we describe the role of PKC isozymes that is involved in cardiac hypertrophy and heart failure. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure". (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:479 / 484
页数:6
相关论文
共 69 条
  • [1] Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy
    Abraham, Prema
    Adelman, Ron A.
    Alfaro, Daniel Virgil, III
    Anand, Rajiv
    Antoszyk, Andrew
    Bergsma, Donald
    Hartnett, Mary Elizabeth
    Brucker, Alexander J.
    Carr, Tyree
    Casey, Raynor C.
    Rubino, John
    Chandler, Thomas W.
    Charles, Steven
    Chaudhry, Nauman
    Combs, James
    Doft, Bernard
    Young, Lucy H. Y.
    Drouilhet, John H.
    Dugel, Pravin U.
    Feman, Stephen S.
    Finkelstein, Daniel
    Foster, Robert E.
    Petersen, Michael R.
    Fox, Gregory
    Garretson, Bruce
    Gieser, Jon P.
    Gentile, Ronald C.
    Giovinazzo, Vincent
    Glazer, Louis
    Goodart, Roy A.
    Gottlieb, Justin
    Greven, Craig
    Grizzard, William S.
    Hainsworth, Dean P.
    Halperin, Lawrence
    Heier, Jeffrey S.
    Jackson, William
    Kubacki, Joseph J.
    Kanter, Eric D.
    Keyser, Bruce
    Kingsley, Ronald
    Ko, Paula
    Kokame, Gregg T.
    Kuppermann, Baruch
    Lambert, H. Michael
    Lewis, Hilel
    Lewis, Richard Alan
    Marcus, Dennis
    Nussbaum, Julian
    Maturi, Raj K.
    [J]. OPHTHALMOLOGY, 2006, 113 (12) : 2221 - 2230
  • [2] A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma
    Advani, R
    Peethambaram, P
    Lum, BL
    Fisher, GA
    Hartmann, L
    Long, HJ
    Halsey, J
    Holmlund, JT
    Dorr, A
    Sikic, BI
    [J]. CANCER, 2004, 100 (02) : 321 - 326
  • [3] Aiello LP, 2007, ARCH OPHTHALMOL-CHIC, V125, P318
  • [4] Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression
    Artham, Surya M.
    Lavie, Carl J.
    Milani, Richard V.
    Patel, Dharmendrakumar A.
    Verma, Anil
    Ventura, Hector O.
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2009, 52 (02) : 153 - 167
  • [5] Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies
    Bernardo, Bianca C.
    Weeks, Kate L.
    Pretorius, Lynette
    McMullen, Julie R.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2010, 128 (01) : 191 - 227
  • [6] CHARACTERIZATION OF PROTEIN-KINASE-C ISOTYPE EXPRESSION IN ADULT-RAT HEART - PROTEIN-KINASE C-EPSILON IS A MAJOR ISOTYPE PRESENT, AND IT IS ACTIVATED BY PHORBOL ESTERS, EPINEPHRINE, AND ENDOTHELIN
    BOGOYEVITCH, MA
    PARKER, PJ
    SUGDEN, PH
    [J]. CIRCULATION RESEARCH, 1993, 72 (04) : 757 - 767
  • [7] Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart
    Bowling, N
    Walsh, RA
    Song, GJ
    Estridge, T
    Sandusky, GE
    Fouts, RL
    Mintze, K
    Pickard, T
    Roden, R
    Bristow, MR
    Sabbah, HN
    Mizrahi, JL
    Gromo, G
    King, GL
    Vlahos, CJ
    [J]. CIRCULATION, 1999, 99 (03) : 384 - 391
  • [8] Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates
    Bowman, JC
    Steinberg, SF
    Jiang, TR
    Geenen, DL
    Fishman, GI
    Buttrick, PM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (09) : 2189 - 2195
  • [9] Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction
    Boyle, AJ
    Kelly, DJ
    Zhang, Y
    Cox, AJ
    Grow, RM
    Way, K
    Itescu, S
    Krum, H
    Gilbert, RE
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2005, 39 (02) : 213 - 221
  • [10] PKC-α regulates cardiac contractility and propensity toward heart failure
    Braz, JC
    Gregory, K
    Pathak, A
    Zhao, W
    Sahin, B
    Klevitsky, R
    Kimball, TF
    Lorenz, JN
    Nairn, AC
    Liggett, SB
    Bodi, I
    Wang, S
    Schwartz, A
    Lakatta, EG
    DePaoli-Roach, AA
    Robbins, J
    Hewett, TE
    Bibb, JA
    Westfall, MV
    Kranias, EG
    Molkentin, JD
    [J]. NATURE MEDICINE, 2004, 10 (03) : 248 - 254